The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Transforming Growth Factor-β1 (TGF-β1)-stimulated Fibroblast to Myofibroblast Differentiation Is Mediated by Hyaluronan (HA)-facilitated Epidermal Growth Factor Receptor (EGFR) and CD44 Co-localization in Lipid Rafts
Open accessAbstract
Fibroblast to myofibroblast differentiation drives effective wound healing and is largely regulated by the cytokine transforming growth factor-β1 (TGF-β1). Myofibroblasts express α-smooth muscle actin and are present in granulation tissue, where they are responsible for wound contraction. Our previous studies show that fibroblast differentiation in response to TGF-β1 is dependent on and mediated by the linear polysaccharide hyaluronan (HA). Both the HA receptor, CD44, and the epidermal growth factor receptor (EGFR) are involved in this differentiation response. The aim of this study was to understand the mechanisms linking HA-, CD44-, and EGFR-regulated TGF-β1-dependent differentiation. CD44 and EGFR co-localization within membrane-bound lipid rafts was necessary for differentiation, and this triggered downstream mitogen-activated protein kinase (MAPK/ERK) and Ca2+/calmodulin kinase II (CaMKII) activation. We also found that ERK phosphorylation was upstream of CaMKII phosphorylation, that ERK activation was necessary for CaMKII signaling, and that both kinases were essential for differentiation. In addition, HA synthase-2 (HAS2) siRNA attenuated both ERK and CaMKII signaling and sequestration of CD44 into lipid rafts, preventing differentiation. In summary, the data suggest that HAS2-dependent production of HA facilitates TGF-β1-dependent fibroblast differentiation through promoting CD44 interaction with EGFR held within membrane-bound lipid rafts. This induces MAPK/ERK, followed by CaMKII activation, leading to differentiation. This pathway is synergistic with the classical TGF-β1-dependent SMAD-signaling pathway and may provide a novel opportunity for intervention in wound healing.Background: Wound healing and scarring are driven by transforming growth factor-β1 (TGF-β1)-dependent fibroblast to myofibroblast differentiation.Results: Cell surface CD44 and epidermal growth factor receptor (EGFR) co-localize in lipid rafts to signal through mitogen-activated protein kinase 1/2 (ERK1/2) and Ca2+/calmodulin kinase II (CaMKII).Conclusion: CD44 moves into lipid rafts in a TGF-β1- and hyaluronan-dependent manner, co-localizes with EGFR, and triggers differentiation.Significance: This pathway presents novel targets for the therapy of wound-healing and fibrosis. Fibroblast to myofibroblast differentiation drives effective wound healing and is largely regulated by the cytokine transforming growth factor-β1 (TGF-β1). Myofibroblasts express α-smooth muscle actin and are present in granulation tissue, where they are responsible for wound contraction. Our previous studies show that fibroblast differentiation in response to TGF-β1 is dependent on and mediated by the linear polysaccharide hyaluronan (HA). Both the HA receptor, CD44, and the epidermal growth factor receptor (EGFR) are involved in this differentiation response. The aim of this study was to understand the mechanisms linking HA-, CD44-, and EGFR-regulated TGF-β1-dependent differentiation. CD44 and EGFR co-localization within membrane-bound lipid rafts was necessary for differentiation, and this triggered downstream mitogen-activated protein kinase (MAPK/ERK) and Ca2+/calmodulin kinase II (CaMKII) activation. We also found that ERK phosphorylation was upstream of CaMKII phosphorylation, that ERK activation was necessary for CaMKII signaling, and that both kinases were essential for differentiation. In addition, HA synthase-2 (HAS2) siRNA attenuated both ERK and CaMKII signaling and sequestration of CD44 into lipid rafts, preventing differentiation. In summary, the data suggest that HAS2-dependent production of HA facilitates TGF-β1-dependent fibroblast differentiation through promoting CD44 interaction with EGFR held within membrane-bound lipid rafts. This induces MAPK/ERK, followed by CaMKII activation, leading to differentiation. This pathway is synergistic with the classical TGF-β1-dependent SMAD-signaling pathway and may provide a novel opportunity for intervention in wound healing. Background: Wound healing and scarring are driven by transforming growth factor-β1 (TGF-β1)-dependent fibroblast to myofibroblast differentiation. Results: Cell surface CD44 and epidermal growth factor receptor (EGFR) co-localize in lipid rafts to signal through mitogen-activated protein kinase 1/2 (ERK1/2) and Ca2+/calmodulin kinase II (CaMKII). Conclusion: CD44 moves into lipid rafts in a TGF-β1- and hyaluronan-dependent manner, co-localizes with EGFR, and triggers differentiation. Significance: This pathway presents novel targets for the therapy of wound-healing and fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290 · cited 1×
“Inwoundhealing, thesemyofibroblasts mediate wound contraction and the formation of a collagen-rich extracellular matrix (4).”
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
Mobility measurement by analysis of fluorescence photobleaching recovery kinetics
Axelrod, D., Koppel, D. E., Schlessinger, J., Elson, E., & Webb, W. W. (1976) · Biophysical Journal · doi:10.1016/s0006-3495(76)85755-4 · Cited by 2,714
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
The myofibroblast in wound healing and fibrocontractive diseases
Gabbiani, G. (2003) · The Journal of Pathology · doi:10.1002/path.1427 · Cited by 1,630
Fibroblasts, myofibroblasts, and wound contraction
Grinnell, F. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.401 · Cited by 1,145
Signaling Properties of Hyaluronan Receptors
Turley, E. A., Noble, P. W., & Bourguignon, L. Y. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r100038200 · Cited by 1,041
Li, Q., Lau, A., Morris, T. J., Guo, L., Fordyce, C. B., & Stanley, E. F. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0346-04.2004 · Cited by 708
Pike, L. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800040-jlr200 · Cited by 493
Evanko, S. P., Angello, J. C., & Wight, T. N. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.1004 · Cited by 487
Cited by
Tumor-associated stromal cells as key contributors to the tumor microenvironment
Bussard, K. M., Mutkus, L., Stumpf, K., Gomez-Manzano, C., & Marini, F. C. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0740-2 · Cited by 746
“Evidence has been provided suggesting that this phenomenon is both a transdifferentiation event [10] and a differentiation event [9], depending on the circumstances.”
BackgroundTGF-β/Smad signaling in renal fibrosis
Meng, X.-M., Tang, P. M.-K., Li, J., & Lan, H. Y. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00082 · Cited by 666
TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis
Principe, D. R., Doll, J. A., Bauer, J., Jung, B., Munshi, H. G., Bartholin, L., Pasche, B., Lee, C., & Grippo, P. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt369 · Cited by 523
Myofibroblasts and Fibrosis: Mitochondrial and Metabolic Control of Cellular Differentiation
Gibb, A. A., Lazaropoulos, M. P., & Elrod, J. W. (2020) · Circulation Research · doi:10.1161/circresaha.120.316958 · Cited by 434
Chen, L., Yang, T., Lu, D.-W., Zhao, H., Feng, Y.-L., Chen, H., Chen, D.-Q., Vaziri, N. D., & Zhao, Y.-Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.090 · Cited by 359
Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy
Barrett, R. L., & Puré, E. (2020) · eLife · doi:10.7554/elife.57243 · Cited by 346
TSG-6: A multifunctional protein with anti-inflammatory and tissue-protective properties
Day, A. J., & Milner, C. M. (2019) · Matrix Biology · doi:10.1016/j.matbio.2018.01.011 · Cited by 306
Astarita, J. L., Cremasco, V., Fu, J., Darnell, M. C., Peck, J. R., Nieves-Bonilla, J. M., Song, K., Kondo, Y., Woodruff, M. C., Gogineni, A., et al. (2015) · Nature Immunology · doi:10.1038/ni.3035 · Cited by 286
The Role of CD44 in Disease Pathophysiology and Targeted Treatment
Jordan, A. R., Racine, R. R., Hennig, M. J. P., & Lokeshwar, V. B. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00182 · Cited by 275
Chowdhury, R., Webber, J. P., Gurney, M., Mason, M. D., Tabi, Z., & Clayton, A. (2015) · Oncotarget · doi:10.18632/oncotarget.2711 · Cited by 272
Self-citationThree subtypes of lung cancer fibroblasts define distinct therapeutic paradigms
Hu, H., Piotrowska, Z., Hare, P. J., Chen, H., Mulvey, H. E., Mayfield, A., Noeen, S., Kattermann, K., Greenberg, M., Williams, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.003 · Cited by 265
Pahuja, R., Seth, K., Shukla, A., Shukla, R. K., Bhatnagar, P., Chauhan, L. K. S., Saxena, P. N., Arun, J., Chaudhari, B. P., Patel, D. K., et al. (2015) · ACS Nano · doi:10.1021/nn506408v · Cited by 260
MMP9: A Tough Target for Targeted Therapy for Cancer
Augoff, K., Hryniewicz-Jankowska, A., Tabola, R., & Stach, K. (2022) · Cancers · doi:10.3390/cancers14071847 · Cited by 255
Genetic Regulation of Fibroblast Activation and Proliferation in Cardiac Fibrosis
Park, S., Ranjbarvaziri, S., Lay, F. D., Zhao, P., Miller, M. J., Dhaliwal, J. S., Huertas-Vazquez, A., Wu, X., Qiao, R., Soffer, J. M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035420 · Cited by 85
Propolis compound inhibits profibrotic TGF-β1/SMAD signalling in human fibroblasts
Randall, L. J., Bajan, S., Tran, T. D., Harvey, R. J., & Russell, F. D. (2025) · Scientific Reports · doi:10.1038/s41598-025-07918-2 · Cited by 9
Metadata
- Authors
- Midgley, A. C., Rogers, M., Hallett, M. B., Clayton, A., Bowen, T., Phillips, A. O., & Steadman, R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 288
- Issue
- 21
- Pages
- 14824-14838
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2090243702
- Cited by
- 296
- References
- 55
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.